Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John T Hunt

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Bioorganic & Medicinal Chemistry Letters|March 23, 2005
Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitorsLouis J Lombardo, Amy Camuso, John Clark, et al.
Plos One|March 27, 2019
Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillanceJinqi Liu, Joshua Curtin, Dan You, et al.
Bioorganic & Medicinal Chemistry Letters|May 16, 2008
Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitorsZhen-Wei Cai, Donna Wei, Gretchen M Schroeder, et al.
ACS Medicinal Chemistry Letters|March 19, 2021
Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer ImmunotherapyLiping Zhang, Emily C Cherney, Xiao Zhu, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2008
Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitorRéjean Ruel, Carl Thibeault, Alexandre L'Heureux, et al.
Bioorganic & Medicinal Chemistry Letters|February 22, 2008
Identification of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Met kinaseGretchen M Schroeder, Xiao-Tao Chen, David K Williams, et al.
Bioorganic & Medicinal Chemistry Letters|April 13, 2023
Synthesis and biological evaluation of biaryl alkyl ethers as inhibitors of IDO1Jay A Markwalder, Aaron J Balog, David K Williams, et al.
Journal of Medicinal Chemistry|February 22, 2008
Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215)Zhen-wei Cai, Yongzheng Zhang, Robert M Borzilleri, et al.
Journal of Medicinal Chemistry|August 12, 2008
Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activitiesKyoung Soon Kim, Liping Zhang, Robert Schmidt, et al.
Journal of Medicinal Chemistry|December 24, 2004
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assaysLouis J Lombardo, Francis Y Lee, Ping Chen, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry Letters|March 23, 2005
Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitorsLouis J Lombardo, Amy Camuso, John Clark, et al.
Plos One|March 27, 2019
Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillanceJinqi Liu, Joshua Curtin, Dan You, et al.
Bioorganic & Medicinal Chemistry Letters|May 16, 2008
Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitorsZhen-Wei Cai, Donna Wei, Gretchen M Schroeder, et al.
ACS Medicinal Chemistry Letters|March 19, 2021
Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer ImmunotherapyLiping Zhang, Emily C Cherney, Xiao Zhu, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2008
Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitorRéjean Ruel, Carl Thibeault, Alexandre L'Heureux, et al.
Bioorganic & Medicinal Chemistry Letters|February 22, 2008
Identification of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Met kinaseGretchen M Schroeder, Xiao-Tao Chen, David K Williams, et al.
Bioorganic & Medicinal Chemistry Letters|April 13, 2023
Synthesis and biological evaluation of biaryl alkyl ethers as inhibitors of IDO1Jay A Markwalder, Aaron J Balog, David K Williams, et al.
Journal of Medicinal Chemistry|February 22, 2008
Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215)Zhen-wei Cai, Yongzheng Zhang, Robert M Borzilleri, et al.
Journal of Medicinal Chemistry|August 12, 2008
Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activitiesKyoung Soon Kim, Liping Zhang, Robert Schmidt, et al.
Journal of Medicinal Chemistry|December 24, 2004
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assaysLouis J Lombardo, Francis Y Lee, Ping Chen, et al.
Pageof 4